GlassScriptPhysician profile
Sean M Thibodeaux
NPI 1720766884
$6,558.19
in general payments reported to CMS, 2019-2025
24 companies · $2,946 in 2025
The $2,946 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $516 · 2024: $3,096 · 2025: $2,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,546 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,546.04 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,374.82 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $817.98 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $501.80 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $479.66 | 2024-2025 | Auvelity |
| Alkermes, INC. | $431.06 | 2023-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $414.05 | 2024-2025 | Dyanavel Xr |
| Lundbeck LLC | $412.93 | 2023-2025 | Rexulti |
| Noven Therapeutics, LLC | $380.58 | 2023-2025 | Xelstrym, Secuado |
| Corium, LLC | $377.56 | 2023-2025 | Azstarys |
| Braeburn INC. | $303.73 | 2023-2024 | Brixadi |
| Vanda Pharmaceuticals INC. | $213.91 | 2024-2025 | Fanapt |
| Bausch Health US, LLC | $135.26 | 2023-2024 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $128.24 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $122.21 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $90.98 | 2024-2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $88.18 | 2023-2024 | Sublocade |
| Ironshore Pharmaceuticals INC. | $84.63 | 2024 | |
| Neos Therapeutics, LP | $54.03 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Teva Pharmaceuticals USA, INC. | $46.41 | 2023 | Austedo Xr |
| Sage Therapeutics, LLC | $35.06 | 2024 | |
| Supernus Pharmaceuticals, INC. | $18.30 | 2024 | Qelbree |
| Collegium Pharmaceutical, INC. | $17.01 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $16.27 | 2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $13.53 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Thibodeaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.